Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Non Operating Income (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Non Operating Income for 16 consecutive years, with -$632.0 as the latest value for Q1 2026.

  • Quarterly Non Operating Income fell 58.0% to -$632.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$13.6 million through Jan 2026, down 140.85% year-over-year, with the annual reading at -$965.0 for FY2025, 100.01% down from the prior year.
  • Non Operating Income for Q1 2026 was -$632.0 at PharmaCyte Biotech, up from -$6.0 million in the prior quarter.
  • The five-year high for Non Operating Income was $24.7 million in Q3 2024, with the low at -$7.5 million in Q3 2025.
  • Average Non Operating Income over 5 years is $1.1 million, with a median of -$253.0 recorded in 2024.
  • The sharpest move saw Non Operating Income skyrocketed 18103.61% in 2022, then tumbled 47416.34% in 2024.
  • Over 5 years, Non Operating Income stood at $438113.0 in 2022, then crashed by 100.17% to -$765.0 in 2023, then crashed by 47416.34% to -$363500.0 in 2024, then crashed by 1562.15% to -$6.0 million in 2025, then surged by 99.99% to -$632.0 in 2026.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$632.0, -$6.0 million, and -$7.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.